StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for MASS yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $7.39 | $6.90 | -6.63% | 0.3M |
| 05-18 | $6.95 | $6.64 | -4.46% | 0.2M |
| 05-19 | $6.55 | $6.78 | +3.51% | 0.2M |
| 05-20 | $6.81 | $6.98 | +2.50% | 0.2M |
| 05-21 | $6.92 | $7.12 | +2.89% | 0.2M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
908 Devices Inc develops a suite of purpose-built handheld devices for point-of-need chemical analysis. Leveraging mass spectrometry, optical spectroscopy, analytics and machine learning technologies, the company makes devices that are smaller and more accessible than conventional laboratory instruments. Its devices, including MX908, ThreatID, XplorIR and VipIR, are used to analyze unknown materials and provide actionable answers in health, safety and defense technology applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure and security threats. The company reimagines mass spectrometry technology by developing smaller, lower-cost and simpler-to-operate devices compared to conventional instruments, and generates maximum revenue from the United States.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $13.38M | $56.20M | $38.82M | $24.81M |
Operating Income | $-12.88M | $-39.42M | $-42.51M | $-26.19M |
Net Income | $-11.96M | $19.49M | $15.31M | $-13.31M |
EPS (Diluted) | $-0.32 | $0.54 | $0.43 | $0.85 |
Total Assets | $186.69M | $190.07M | $190.87M | $191.70M |
Total Liabilities | $52.52M | $46.37M | $54.57M | $42.88M |
Cash & Equivalents | $67.56M | $70.52M | $62.80M | $61.75M |
Free Cash Flow OCF − CapEx | $1.17M | $-24.64M | $-25.97M | $-21.08M |
Shares Outstanding | 37.41M | 36.32M | 36.12M | 36.06M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.